⚖ Lecture 9 · Comprehensive Revision Tutorial
Eight modules, one lifecycle: L1–L8 each build a module; L9 reassembles them — and keeps patents and regulatory exclusivities apart.
103 · L9 Comprehensive Revision Tutorial
Master Logic
- L9 is the consolidation lecture: L1–L8 each build one module; L9 reassembles them into a single lifecycle.
- Eight modules, one chain: IP fundamentals → patentability → portfolio strategy → ethics → commercial → PCT → litigation → business models. The order runs from tool to deal.
- Where marks are lost: applying concepts to a fact pattern, comparing jurisdictions (US / EU / China), and stating a case's holding precisely.
- The single most confused point: patents and regulatory exclusivities are two independent systems that stack.
Eight Modules, One Lifecycle
| # | Module | Core question | Lecture |
|---|---|---|---|
| 01 | IP Fundamentals | What rights exist, how long, how broad | L1 |
| 02 | Patentability in Biotech | What is patentable, what is excluded, claims and FTO | L2 |
| 03 | Strategic Portfolio Building | The 5W framework, ownership, common mistakes | L6 |
| 04 | Ethics & Controversial Cases | Invention vs discovery; US / EU / China differences | L3 |
| 05 | Commercial Aspects | Pipeline, exclusivity, diligence, deals | L4 |
| 06 | PCT International Filing | Priority, PCT timeline, national phase | L8 |
| 07 | Litigation & Disputes | Court systems, patent linkage, biosimilars | L5 |
| 08 | Business Models & Future | Five archetypes, the IP–BM flywheel, AI / CRISPR | L7 |
① The five IP rights
| Right | Protects | Biotech example | Term | Core right |
|---|---|---|---|---|
| Patent | Inventions: product, process, composition | New chemical entity, antibody, manufacturing process | 20 years from filing | Exclude others from making / using / selling |
| Trade secret | Confidential business information | Cell line, process parameters, formulation | Unlimited | Protection against unlawful acquisition |
| Trademark | Source identifier | Brand name, logo, trade dress | Renewable | Prevent confusion; requires distinctiveness |
| Copyright | Original expression (not ideas) | Manuals, software, data visualisation | Life + 70 years | Control reproduction; independent creation does not infringe |
| Design | Product appearance | Device shape, packaging, UI layout | Up to 15 years | Decorative appearance only — not function |
Trade secret vs patent
A trade secret lasts forever but dies on independent development or reverse engineering. A patent requires full disclosure in exchange for a limited monopoly. Rule of thumb: reverse-engineerable (structure, formulation) → patent; not reverse-engineerable (cell line, process know-how) → trade secret.
② Patentability: the three gates
- Novelty — nothing identical disclosed anywhere in the world before the filing date. Prior art includes any written, oral or public-use disclosure. Grace period: US 12 months; EU 0 (absolute novelty).
- Inventive step — not obvious to the person skilled in the art. Rebuttals: unexpected effect, teaching away, commercial success.
- Written description / enablement — the specification must teach the skilled person to make and use the whole claimed scope without undue experimentation. This is what kills broad biotech claims.
US judicial exceptions: laws of nature, natural phenomena, abstract ideas, natural products (Myriad, 2013), diagnostic correlations (Mayo, 2012). Ways around: add a practical application, claim an engineered construct / cDNA / modified sequence, add unconventional steps, tie the claim to manipulation rather than discovery.
② Five landmark decisions
| Case | Year | Holding | Why it matters |
|---|---|---|---|
| Diamond v. Chakrabarty | 1980 | Genetically engineered bacteria are patentable subject matter | Opened biotech patenting |
| Moore v. Regents | 1990 | No continuing property right in excised cells | Ethics: commodifying tissue, informed consent |
| Mayo v. Prometheus | 2012 | Claim to a diagnostic dosing correlation invalid | Narrowed diagnostic claims |
| AMP v. Myriad | 2013 | Isolated genomic DNA not patentable; cDNA is | Ended US gene patents; BRCA testing |
| Ariosa v. Sequenom | 2015 | Prenatal diagnostic claim invalid under Mayo | Shows post-2012 difficulty for diagnostics |
③ Portfolio strategy: the 5W framework
| W | Question | In practice |
|---|---|---|
| WHY | Commercial goal | Offence, defence, licensing revenue, investor story, freedom to operate |
| WHAT | What to protect | Compound / method, formulation / dosing, second medical use, biomarker, process (trade secret), brand |
| WHERE | Which jurisdictions | Manufacturing, use and sales markets; competitor home turf; regulatory listing (Orange Book / NMPA linkage) |
| WHEN | Timing | Before any public disclosure; aligned with publication, fundraising, trial start, launch |
| WHO | Ownership | Inventor residence, place of invention, employment / consultancy contracts, university vs company, foreign filing licence (FFL) |
Core principle
File before you publish. One public disclosure can destroy global novelty — the only exception is the US 12-month grace period.
③ Six fatal mistakes
- Publishing before filing — conference abstracts, posters and investor pitches all destroy EU / China novelty.
- Getting claim scope wrong — too broad fails enablement; too narrow is designed around.
- Confusing inventorship with ownership — inventors contribute to the claims; ownership follows contracts. Wrong inventors can invalidate.
- Missing the foreign filing licence — in China, inventions made in China need FFL before filing abroad.
- Ignoring FTO — "you have a patent" does not mean "you may operate".
- Ignoring the trade-secret/patent trade-off — reverse-engineerable process → patent; otherwise secret.
④ Ethics: invention vs discovery by jurisdiction
| Issue | US | EPO | China (CNIPA) |
|---|---|---|---|
| Isolated gene / DNA | Not patentable (Myriad); cDNA yes | Patentable with technical effect / industrial application | Patentable with a specific use |
| Transgenic animals | Patentable (Harvard mouse) | Patentable, balanced by Art. 53(a) | Partly patentable, statutory and moral limits |
| Diagnostic methods | Narrowed by Mayo | Excluded as such (Art. 53) | Excluded (Art. 25) |
| Moral threshold | No moral clause | Strong moral clause; human body and germline excluded | Moral clause (Art. 5); embryos and germline editing excluded |
⑤ Commercial: where IP sits in development
| Stage | IP activity |
|---|---|
| Discovery | Compound patent, method of use, trade secret (process) |
| Preclinical | Formulation patent, second medical use, data exclusivity starts accruing |
| Clinical I–III | Orange Book listing, data exclusivity clock, orphan exclusivity |
| Review / approval | SPC / PTE filing, new dose or formulation, paediatric exclusivity |
| Post-market | Patent linkage litigation, biosimilar patent dance, skinny-label disputes |
GLP (preclinical) → GCP (clinical) → GMP (manufacture). Lab → Clinic → Manufacture.
⑤b Patents vs regulatory exclusivity
| Exclusivity | US | EU | China |
|---|---|---|---|
| Base patent term | 20 years from filing | 20 years | 20 years |
| Extension | PTE up to +5 years | SPC up to 5 years; 8+2(+1) | Up to 5 years; SPC pilot since 2021 |
| Data exclusivity | 5 years (NCE) + 3 years (new indication); biologics 12 years | 8+2(+1) | 6 years chemical / 12 years biologic |
| Orphan | 7 years | 10 years | Incentives under development |
| Paediatric | +6 months | +6 months SPC | Being developed |
The one sentence to remember
A patent blocks others from making, using or selling; regulatory exclusivity blocks others from relying on your data. They are independent and can stack.
⑤c Due diligence: six questions and the deal menu
- What exactly is owned, and by whom?
- Is the chain of title clean (inventors, assignments, university rights)?
- How broad and how durable is the protection (term, geography, FTO)?
- What is the regulatory position (approvals, exclusivity, linkage)?
- What litigation or opposition risk exists?
- What is the deal structure (licence, co-development, M&A, option, milestone/royalty)?
⑥ PCT: buying time, keeping options
A PCT application does not grant a patent; it preserves the option to enter national phase in up to ~150 states, typically 30 months from priority. It buys 18 months of extra time to raise money, generate data and decide where to spend.
⑦ Litigation: unified (US) vs bifurcated (China)
In the US, validity and infringement are decided in the same court. In China, invalidity goes to CNIPA on a separate track, so a defendant cannot simply plead "invalid" in the infringement action; there is also no US-style discovery, so who holds the documents becomes a battleground.
⑦ Patent linkage and biosimilars
Patent linkage ties generic/biosimilar approval to the patent status of the reference product (Hatch-Waxman in the US; the NMPA linkage regime in China). Four certification statements exist, and a carve-out is not full immunity — label, marketing and promotion must align.
⑧ Five business models — IP strategy follows the model
| Model | IP posture |
|---|---|
| Fully integrated biopharma | Broad, deep portfolio; global filing; litigation capability |
| Platform / technology company | Patent the platform, license to many partners |
| Asset-centric / virtual | Narrow but strong; out-license after proof of concept |
| Service / CDMO | Process know-how as trade secret; fewer patents |
| Generic / biosimilar | Design-around, invalidity challenges, first-to-file incentives |
Future: AI-generated inventions (inventorship), complex biologics (claiming what you can enable), CRISPR (broad versus narrow genus claims).
Six Things to Remember
- Patents and regulatory exclusivities are independent and stack.
- File before you publish — only the US gives 12 months.
- Claim breadth is a trade-off against enablement.
- Inventorship is a validity issue, not paperwork.
- Trade secret versus patent is decided by reverse-engineerability.
- IP strategy must follow the business model, not the reverse.
Key Terms
| Term | Meaning |
|---|---|
| FTO | Freedom to operate: whether your product infringes others' rights |
| SPC / PTE | Supplementary protection certificate (EU) / patent term extension (US) |
| FFL | Foreign filing licence (required in China for inventions made in China) |
| PCT | Patent Cooperation Treaty: one application, many national phases |
| Orange Book | US FDA list of approved products and related patents |
| Patent linkage | Tying generic approval to the reference product's patent status |
One-line Summary
English: One lifecycle, eight modules — rights, gates, portfolio, ethics, deals, PCT, litigation, business model — and every step trades protection scope against enforceability.
中文邏輯：五類 IP → 三道閘門 → 5W 組合 → 倫理 → 交易 → PCT → 訴訟 → 商業模式，每一步都在「守得多寬」與「守不守得住」之間取捨。
中文邏輯：五類 IP → 三道閘門 → 5W 組合 → 倫理 → 交易 → PCT → 訴訟 → 商業模式，每一步都在「守得多寬」與「守不守得住」之間取捨。